内容紹介
Summary
The patient was a 68-year-old woman. She was diagnosed with invasive thymoma 12 years prior and underwent chemoradiotherapy(adriamycin, cisplatin, vincristine, and cyclophosphamide: ADOC)plus radiation exposure(62 Gy). After 11 years, the disease relapsed. Carboplatin plus paclitaxel(CP)therapy as a second-line therapy was ineffective, leading to enlargement of the primary tumor and the development of pleurisy. The third-line treatment with a single dose of amrubicin resulted in good disease control. There were no serious adverse events, and the drug tolerance was good. The patient has undergone 21 courses of this treatment as of the time of this report and continues to maintain complete response(CR). No chemotherapy regimen as more than a second-line therapy demonstrated efficacy against recurrent thymoma. Amrubicin monotherapy may be an effective treatment option that may result in long-term survival with minor side effects.
要旨
症例は68歳,女性。12年前に浸潤性胸腺腫と診断し,化学放射線療法(アドリアマイシン+シスプラチン+ビンクリスチン+シクロホスファミド: ADOC)+放射線照射(62 Gy)後11年経過して再発した。二次治療のカルボプラチン+パクリタキセル(CP)療法は効果が乏しく,早期に原発巣の増大と胸膜炎を発症した。三次治療としてアムルビシン単剤にて治療し良好な病勢制御を得た。重篤な有害事象は認めず忍容性は良好で,本稿執筆時には21コース施行後であるが依然としてcomplete response(CR)を維持している。再発性胸腺腫に対して有効性の証明された二次治療以降の化学療法レジメンは存在しない。アムルビシン単剤治療は副作用が軽微で長期生存を期待できる有効な治療選択肢となり得る。
目次
The patient was a 68-year-old woman. She was diagnosed with invasive thymoma 12 years prior and underwent chemoradiotherapy(adriamycin, cisplatin, vincristine, and cyclophosphamide: ADOC)plus radiation exposure(62 Gy). After 11 years, the disease relapsed. Carboplatin plus paclitaxel(CP)therapy as a second-line therapy was ineffective, leading to enlargement of the primary tumor and the development of pleurisy. The third-line treatment with a single dose of amrubicin resulted in good disease control. There were no serious adverse events, and the drug tolerance was good. The patient has undergone 21 courses of this treatment as of the time of this report and continues to maintain complete response(CR). No chemotherapy regimen as more than a second-line therapy demonstrated efficacy against recurrent thymoma. Amrubicin monotherapy may be an effective treatment option that may result in long-term survival with minor side effects.
要旨
症例は68歳,女性。12年前に浸潤性胸腺腫と診断し,化学放射線療法(アドリアマイシン+シスプラチン+ビンクリスチン+シクロホスファミド: ADOC)+放射線照射(62 Gy)後11年経過して再発した。二次治療のカルボプラチン+パクリタキセル(CP)療法は効果が乏しく,早期に原発巣の増大と胸膜炎を発症した。三次治療としてアムルビシン単剤にて治療し良好な病勢制御を得た。重篤な有害事象は認めず忍容性は良好で,本稿執筆時には21コース施行後であるが依然としてcomplete response(CR)を維持している。再発性胸腺腫に対して有効性の証明された二次治療以降の化学療法レジメンは存在しない。アムルビシン単剤治療は副作用が軽微で長期生存を期待できる有効な治療選択肢となり得る。